Denali therapeutics announces dnl343 interim phase 1b data in als and entry into the healey als platform trial

South san francisco, calif., dec. 05, 2022 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases and lysosomal storage disorders, today announced interim results from a phase 1b study of its eif2b agonist, dnl343, in participants with amyotrophic lateral sclerosis (als). once-daily oral dosing with dnl343 for 28 days was generally well tolerated and demonstrated extensive bbb penetration as well as robust inhibition of biomarkers associated with the integrated stress response (isr) in blood samples from study participants. by inhibiting the isr pathway, dnl343 is intended to prevent or slow disease progression associated with stress granule formation and tdp-43 aggregation, a hallmark pathology present in nearly all individuals with als. the phase 1b results will be presented at the 33rd international symposium on als/mnd, which is being held virtually december 6-9, 2022. a copy of the poster presentation is available on denali's website on the investor & media relations section under the events page. denali also announced initiation of the design phase of a phase 2/3 study for entry into the healey als platform trial led by the sean m. healey & amg center for als at massachusetts general hospital (mgh) in collaboration with the northeast als consortium.
DNLI Ratings Summary
DNLI Quant Ranking